Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study confirmed that a sulfotransferase enzyme test can effectively rule out 95.9% of nonresponders to 5% topical minoxidil for treating androgenetic alopecia.

Minoxidil response testing helps predict hair growth success.

A hair test can accurately predict if a person with hair loss will respond to minoxidil treatment.

This study found that applying topical tretinoin can influence follicular sulfotransferase expression, enabling 43% of predicted nonresponders to minoxidil to respond positively in the context of androgenetic alopecia.

This study found that SULT1A1 enzyme activity, crucial for activating minoxidil, is significantly lower in eyebrow and eyelash follicles compared to scalp follicles, suggesting that additional sulfotransferase supplementation might enhance minoxidil-based hair growth treatments for these areas.

This study found that sulfotransferase enzyme levels significantly impact the effectiveness of minoxidil in treating androgenetic alopecia, suggesting that testing for this enzyme could help identify potential responders before treatment.

This study found a perfect correlation between laser Doppler velocimetry measurements of scalp blood perfusion after minoxidil application and sulfotransferase enzyme activity in hair follicles, indicating a potential non-invasive test to predict minoxidil response in female pattern hair loss.

Treatments for hair loss include hormone modifiers, minoxidil, and hair transplant surgery.

This study reviewed the evidence on minoxidil's effectiveness for androgenetic alopecia, finding that 5% topical minoxidil is the most effective monotherapy for men, while 2% is similarly effective for women. Genetic markers can predict response, and new formulations like foam and gel improve tolerability.

This study found that laser Doppler velocimetry can non-invasively predict topical minoxidil response by correlating scalp blood flow changes with sulfotransferase enzyme activity in women with pattern hair loss.

This study characterized the activity of naturally occurring minoxidil sulfotransferase enzymes in various plants and found that seven out of ten botanical extracts showed significant activity, suggesting these could potentially enhance minoxidil response in treating androgenetic alopecia.

This article discusses expert responses to hair loss in women but reports no new research findings.

This study explored the molecular mechanisms by which Polygonum multiflorum may treat androgenic alopecia, suggesting it influences cell apoptosis and inflammation through specific pathways, with potential application value pending further testing.

Minoxidil solution helps hair regrowth in alopecia areata, with 5% being more effective.

This study found that the combination of PRP with topical minoxidil and finasteride showed the most significant improvement in hair pull tests and patient satisfaction for male androgenetic alopecia, surpassing individual therapies and placebo over a six-month period.

This article describes cases of allergic contact dermatitis triggered by minoxidil but provides no new clinical findings.

Minoxidil helps increase hair growth and density in people with hair loss, with higher concentrations giving better results.

This review discusses treatments for androgenic alopecia, including minoxidil, finasteride, and hormonal therapies with antiandrogens, and reports no new clinical findings.

This article discusses scalp neuropathy in androgenetic alopecia and suggests that changes in tactile sensation due to Aβ fibers and increased nociception from circ-HTMR may be involved.

This article discusses the causes, diagnosis, and treatment options for female pattern hair loss, emphasizing the role of topical minoxidil as a primary treatment, but provides no new clinical results.

This review highlights the various causes and treatment options for alopecia, noting that while non-scarring types often see successful hair regrowth, scarring forms require early intervention to manage inflammatory destruction of hair follicles.

This study reports that the prevalence of female pattern hair loss increases with age, affecting 12% of women by age 29, 25% by age 50, and 41% to 50% by age 70 and older, with risk factors including genetics and certain endocrinological conditions.

This study observed that Platycarya strobilacea S. et Z. extract enhanced hair growth and improved hair follicle length and immune response in mice compared to control groups.

Certain hairstyles can cause scalp diseases, smoking is linked to hair loss, 5% minoxidil foam is effective for hair loss treatment, and various factors influence wound healing and hair growth.

This study suggests that COVID-19 infection can lead to telogen effluvium, typically occurring 3-6 months post-infection, potentially linked to the virus's inflammatory and anticoagulation effects.

This article outlines the clinical features, evaluation, and treatment strategies for androgen excess in polycystic ovary syndrome, highlighting important diagnostic and management approaches but reporting no new research results.

In this study, researchers examined men with early-stage androgenetic alopecia and found distinct patterns of hair loss correlated with genetic and hormonal factors, noting that parietal region pattern hair loss responded better to minoxidil and micronutrient treatment compared to occipital region pattern.

Telogen Effluvium is a hair loss condition where treatment involves identifying and managing its triggers.

This review discusses the classifications, diagnostic methods, and treatment strategies for female pattern hair loss, but reports no clinical results.

This review discusses the roles of androgens and estrogens in skin functions and disorders, and highlights the use of estrogen-progestin treatments and anti-androgens in managing hirsutism and acne, without reporting new results.